RESUMO
OBJECTIVES: Polymyxin-induced nephrotoxicity (PIN) is a major safety concern and challenge in clinical practice, which limits the clinical use of polymyxins. This study aims to investigate the risk factors and to develop a scoring tool for the early prediction of PIN. METHODS: Data on critically ill patients who received intravenous polymyxin B or colistin sulfate for over 24 h were collected. Logistic regression with the least absolute shrinkage and selection operator (LASSO) was used to identify variables that are associated with outcomes. The eXtreme Gradient Boosting (XGB) classifier algorithm was used to further visualize factors with significant differences. A prediction model for PIN was developed through binary logistic regression analysis and the model was assessed by temporal validation and external validation. Finally, a risk-scoring system was developed based on the prediction model. RESULTS: Of 508 patients, 161 (31.6%) patients developed PIN. Polymyxin type, loading dose, septic shock, concomitant vasopressors and baseline blood urea nitrogen (BUN) level were identified as significant predictors of PIN. All validation exhibited great discrimination, with the AUC of 0.742 (95% CI: 0.696-0.787) for internal validation, of 0.708 (95% CI: 0.605-0.810) for temporal validation and of 0.874 (95% CI: 0.759-0.989) for external validation, respectively. A simple risk-scoring tool was developed with a total risk score ranging from -3 to 4, corresponding to a risk of PIN from 0.79% to 81.24%. CONCLUSIONS: This study established a prediction model for PIN. Before using polymyxins, the simple risk-scoring tool can effectively identify patients at risk of developing PIN within a range of 7% to 65%.
Assuntos
Antibacterianos , Humanos , Feminino , Masculino , Estudos Retrospectivos , Pessoa de Meia-Idade , Antibacterianos/efeitos adversos , Idoso , Fatores de Risco , Polimixina B/efeitos adversos , Polimixina B/administração & dosagem , Projetos Piloto , Estado Terminal , Medição de Risco/métodos , Polimixinas/efeitos adversos , Colistina/efeitos adversos , Colistina/administração & dosagem , Modelos Logísticos , Adulto , Nefropatias/induzido quimicamenteRESUMO
OBJECTIVES: Central nervous system (CNS) infections caused by carbapenem-resistant Gram-negative bacteria (CR-GNB) present a major health and economic burden worldwide. This multicentre prospective study aimed to assess the feasibility and usefulness of CSF therapeutic drug monitoring (TDM) after intrathecal/intraventricular administration of polymyxin B in patients with CNS infections. METHODS: Forty-two patients treated with intrathecal/intraventricular administration of polymyxin B against CR-GNB-induced CNS infections were enrolled. CSF trough level (Cmin) was collected beginning on Day 2 post-polymyxin B initiation and thereafter. The primary outcomes were clinical cure and 28-day all-cause mortality. RESULTS: All patients started with intrathecal/intraventricular administration of polymyxin B at a dose of 5 g/day, corresponding to a median CSF Cmin of 2.93 mg/L (range, 0.21-25.74 mg/L). Clinical cure was 71.4%, and the median CSF Cmin of this group was higher than that of clinical failure group [3.31 (IQR, 1.73-5.62) mg/L versus 2.25 (IQR, 1.09-4.12) mg/L; Pâ=â0.011]. In addition, with MICsâ≤â0.5 mg/L, maintaining polymyxin B CSF Cmin above 2.0 mg/L showed a higher clinical cure rate (Pâ=â0.041). The 28-day all-cause mortality rate was 31.0% and had no association with CSF Cmin. CONCLUSIONS: After intrathecal/intraventricular administration of polymyxin B, CSF concentrations fluctuated considerably inter- and intra-individual. Polymyxin B CSF Cmin above 2.0 mg/L was associated with clinical cure when MICs wereâ≤â0.5 mg/L, and the feasibility of TDM warrants additional clinical studies.
Assuntos
Antibacterianos , Carbapenêmicos , Monitoramento de Medicamentos , Bactérias Gram-Negativas , Infecções por Bactérias Gram-Negativas , Polimixina B , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Polimixina B/uso terapêutico , Polimixina B/administração & dosagem , Polimixina B/farmacocinética , Antibacterianos/líquido cefalorraquidiano , Antibacterianos/uso terapêutico , Antibacterianos/farmacocinética , Antibacterianos/administração & dosagem , Estudos Prospectivos , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Infecções por Bactérias Gram-Negativas/líquido cefalorraquidiano , Infecções por Bactérias Gram-Negativas/mortalidade , Infecções por Bactérias Gram-Negativas/microbiologia , Carbapenêmicos/uso terapêutico , Carbapenêmicos/farmacocinética , Carbapenêmicos/farmacologia , Idoso , Bactérias Gram-Negativas/efeitos dos fármacos , Adulto , Infecções do Sistema Nervoso Central/tratamento farmacológico , Infecções do Sistema Nervoso Central/líquido cefalorraquidiano , Infecções do Sistema Nervoso Central/microbiologia , Infecções do Sistema Nervoso Central/mortalidade , Injeções Espinhais , Resultado do Tratamento , Testes de Sensibilidade Microbiana , Líquido Cefalorraquidiano/microbiologiaRESUMO
PURPOSE: Post-neurosurgical intracranial infection caused by carbapenem-resistant gram-negative bacteria (CRGNB) is a life-threatening complication. This study aimed to assess the current practices and clinical outcomes of intravenous (IV) combined with intraventricular (IVT)/intrathecal (ITH) polymyxin B in treating CRGNB intracranial infection. METHODS: A retrospective study was conducted on patients with post-neurosurgical intracranial infection due to CRGNB from January 2013 to December 2020. Clinical characteristics and treatment outcomes were collected and described. Kaplan-Meier survival and multivariate logistic regression analyses were performed. RESULTS: The study included 114 patients, of which 72 received systemic antimicrobial therapy combined with IVT/ITH polymyxin B, and 42 received IV administration alone. Most infections were caused by carbapenem-resistant Acinetobacter baumannii (CRAB, 63.2%), followed by carbapenem-resistant Klebsiella pneumoniae (CRKP, 31.6%). Compared with the IV group, the IVT/ITH group had a higher cerebrospinal fluid (CSF) sterilization rate in 7 days (p < 0.001) and lower 30-day mortality (p = 0.032). In the IVT/ITH group, patients with CRKP infection had a higher initial fever (p = 0.014), higher incidence of bloodstream infection (p = 0.040), lower CSF sterilization in 7 days (p < 0.001), and higher 30-day mortality (p = 0.005) than those with CRAB infection. Multivariate logistic regression analysis revealed that the duration of IVT/ITH polymyxin B (p = 0.021) was independently associated with 30-day mortality. CONCLUSIONS: Intravenous combined with IVT/ITH polymyxin B increased CSF microbiological eradication and improved clinical outcomes. CRKP intracranial infections may lead to more difficult treatment and thus warrant attention and further optimized treatment.
Assuntos
Antibacterianos , Carbapenêmicos , Bactérias Gram-Negativas , Infecções por Bactérias Gram-Negativas , Polimixina B , Humanos , Polimixina B/uso terapêutico , Polimixina B/administração & dosagem , Masculino , Feminino , Estudos Retrospectivos , Pessoa de Meia-Idade , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Carbapenêmicos/farmacologia , Carbapenêmicos/uso terapêutico , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Infecções por Bactérias Gram-Negativas/microbiologia , Infecções por Bactérias Gram-Negativas/mortalidade , Bactérias Gram-Negativas/efeitos dos fármacos , Idoso , Adulto , Injeções Espinhais , Procedimentos Neurocirúrgicos/efeitos adversos , Resultado do Tratamento , Injeções IntraventricularesRESUMO
BACKGROUND AND OBJECTIVES: Despite being clinically utilized for the treatment of infections, the limited therapeutic range of polymyxin B (PMB), along with considerable interpatient variability in its pharmacokinetics and frequent occurrence of acute kidney injury, has significantly hindered its widespread utilization. Recent research on the population pharmacokinetics of PMB has provided valuable insights. This study aims to review relevant literature to establish a theoretical foundation for individualized clinical management. METHODS: Follow PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, Pop-PK studies of PMB were searched in PubMed and EMBASE database systems from the inception of the database until March 2023. RESULT: To date, a total of 22 population-based studies have been conducted, encompassing 756 subjects across six different countries. The recruited population in these studies consisted of critically infected individuals with multidrug-resistant bacteria, patients with varying renal functions, those with cystic fibrosis, kidney or lung transplant recipients, patients undergoing extracorporeal membrane oxygenation (ECMO) or continuous renal replacement therapy (CRRT), as well as individuals with obesity or pediatric populations. Among these studies, seven employed a one-compartmental model, with the range of typical clearance (CL) and volume (Vc) being 1.18-2.5L /h and 12.09-47.2 L, respectively. Fifteen studies employed a two-compartmental model, with the ranges of the clearance (CL) and volume of the central compartment (Vc), the volume of the peripheral compartment (Vp), and the intercompartment clearance (Q) were 1.27-8.65 L/h, 5.47-38.6 L, 4.52-174.69 L, and 1.34-24.3 L/h, respectively. Primary covariates identified in these studies included creatinine clearance and body weight, while other covariates considered were CRRT, albumin, age, and SOFA scores. Internal evaluation was conducted in 19 studies, with only one study being externally validated using an independent external dataset. CONCLUSION: We conclude that small sample sizes, lack of multicentre collaboration, and patient homogeneity are the primary reasons for the discrepancies in the results of the current studies. In addition, most of the studies limited in the internal evaluation, which confined the implementation of model-informed precision dosing strategies.
Assuntos
Antibacterianos , Polimixina B , Humanos , Polimixina B/farmacocinética , Polimixina B/administração & dosagem , Antibacterianos/farmacocinética , Antibacterianos/administração & dosagem , Modelos Biológicos , Oxigenação por Membrana Extracorpórea , Estado TerminalRESUMO
BACKGROUND: Polymyxins have re-emerged as a last-resort therapeutic option for infections caused by carbapenem-resistant gram-negative bacteria. Nephrotoxicity induced by polymyxins is a significant limitation of its use in the clinic. Polymyxin B and colistin sulfate are two widely used active formulations of polymyxins. However, there is a lack of studies conducting a comparative assessment of nephrotoxicity between the two formulations. This study aimed to compare the nephrotoxicity of polymyxin B and colistin sulfate in critically ill patients. METHODS: We conducted a retrospective cohort study among critically ill patients who received intravenous polymyxin B or colistin sulfate for over 48 h from January 2017 to January 2024. The primary outcome was the incidence of acute kidney injury (AKI) associated with polymyxins, and the secondary outcome was 30-day all-cause mortality. Additionally, the risk factors of polymyxins-induced AKI and 30-day all-cause mortality were identified by Cox proportional hazard regression analysis. RESULTS: A total of 473 patients were included in this study. The overall incidence of AKI was significantly higher in patients who received polymyxin B compared to those who received colistin sulfate in the unmatched cohort (20.8% vs. 9.0%, p = 0.002) and in the propensity score matching cohort (21.1% vs. 7.0%, p = 0.004), respectively. However, there was no significant difference in 30-day all-cause mortality between the two groups. Polymyxin type, septic shock, and concomitant use of vasopressors were identified as independent risk factors for polymyxin-induced AKI. CONCLUSIONS: The prevalence of AKI was higher among patients who received polymyxin B compared to those treated with colistin sulfate. However, there was no significant difference in 30-day all-cause mortality between the two groups. Further prospective, multicenter studies with larger sample sizes are needed to validate these findings.
Assuntos
Injúria Renal Aguda , Antibacterianos , Colistina , Estado Terminal , Polimixina B , Humanos , Colistina/efeitos adversos , Colistina/administração & dosagem , Polimixina B/efeitos adversos , Polimixina B/administração & dosagem , Polimixina B/uso terapêutico , Injúria Renal Aguda/induzido quimicamente , Injúria Renal Aguda/epidemiologia , Estudos Retrospectivos , Masculino , Feminino , Pessoa de Meia-Idade , Antibacterianos/efeitos adversos , Antibacterianos/administração & dosagem , Idoso , Estudos de Coortes , Administração Intravenosa , Incidência , Fatores de RiscoRESUMO
Extracorporeal blood purification with polymyxin B immobilized fiber column direct hemoperfusion (PMX-DHP), is reported to be effective in treating COVID-19 pneumonitis with oxygen demand. This multicenter prospective study evaluated the efficacy and safety of PMX-DHP in oxygen-requiring patients with COVID-19 admitted between September 28, 2020, and March 31, 2022. The primary endpoint was the percentage of clinical improvement 15 days after treatment. The secondary endpoint was the percentage of worsened disease status. Data from the COVID-19 patient registry were used for the synthetic control group. The improvement rate on Day 15 did not differ between PMX-treated patients and controls; however, the deterioration rate was 0.38 times lower in the PMX-treated group, and the death rates on Day 29 were 0 and 11.1% in the PMX-treated and control groups, respectively. The PMX group showed a 0.73 times higher likelihood for reduced intensive care demand, as 16.7% of PMX-treated patients and 22.8% of controls worsened. After treatment blood oxygenation improved, urinary ß2-microglobulin and liver-type fatty acid-binding protein showed significant decreases, and IL-6 decreased once during treatment but did not persist. In this study, PMX treatment effectively prevented the worsening of COVID-19 pathology, accompanied by improved oxygenation. PMX treatment to remove activated cells may effectively improve patient outcomes.
Assuntos
COVID-19 , Hemoperfusão , Polimixina B , Humanos , COVID-19/terapia , Polimixina B/administração & dosagem , Polimixina B/uso terapêutico , Masculino , Feminino , Hemoperfusão/métodos , Pessoa de Meia-Idade , Idoso , Estudos Prospectivos , SARS-CoV-2/isolamento & purificação , Resultado do Tratamento , Oxigênio , Oxigenoterapia/métodos , Antibacterianos/uso terapêutico , Antibacterianos/administração & dosagemRESUMO
Diabetic wounds are characterized by chronic trauma, with long-term non-healing attributed to persistent inflammation and recurrent bacterial infections. Exacerbation of the inflammatory response is largely due to increased levels of reactive oxygen species (ROS). In this study, catalase (CAT) was used as a biological template to synthesize nanozyme-supported natural enzymes (CAT-Mn(SH)x) using a biomimetic mineralization method. Subsequently, polymyxin B (CAT-Mn(SH)x@PMB) was immobilized on its surface through electrostatic assembly. CAT-Mn(SH)x@PMB demonstrates the ability for slow and sustained release of hydrogen sulfide (H2S). Finally, CAT-Mn(SH)x@PMB loaded microneedles (MNs) substrate were synthesized using polyvinyl alcohol (PVA) and hydroxyethyl methacrylate (HEMA), and named CAT-(MnSH)x@PMB-MNs. It exhibited enhanced enzyme and antioxidant activities, along with effective antibacterial properties. Validation findings indicate that it can up-regulate the level of M2 macrophages and reduce the level of pro-inflammatory cytokine tumor necrosis factor-α (TNF-α). Additionally, it promotes angiogenesis and rapid nerve regeneration, thereby facilitating wound healing through its dual anti-inflammatory and antibacterial effects. Hence,this study introduces a time-space tissue-penetrating and soluble microneedle patch with dual anti-inflammatory and antibacterial effects for the treatment of diabetic wounds.
Assuntos
Antibacterianos , Catalase , Agulhas , Polimixina B , Cicatrização , Polimixina B/farmacologia , Polimixina B/química , Polimixina B/administração & dosagem , Antibacterianos/farmacologia , Antibacterianos/química , Antibacterianos/administração & dosagem , Animais , Catalase/metabolismo , Catalase/química , Cicatrização/efeitos dos fármacos , Camundongos , Escherichia coli/efeitos dos fármacos , Diabetes Mellitus Experimental/tratamento farmacológico , Ratos , Células RAW 264.7 , Testes de Sensibilidade Microbiana , Tamanho da PartículaRESUMO
INTRODUCTION: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB). METHODOLOGY: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared. RESULTS: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously. CONCLUSIONS: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects.
Assuntos
Antibacterianos , Colistina , Pneumonia Bacteriana , Polimixina B , Humanos , Polimixina B/uso terapêutico , Polimixina B/administração & dosagem , Masculino , Colistina/uso terapêutico , Colistina/efeitos adversos , Colistina/administração & dosagem , Feminino , Antibacterianos/uso terapêutico , Pessoa de Meia-Idade , Idoso , Pneumonia Bacteriana/tratamento farmacológico , Pneumonia Bacteriana/microbiologia , Estudos Retrospectivos , Acinetobacter baumannii/efeitos dos fármacos , Infecções por Bactérias Gram-Negativas/tratamento farmacológico , Resultado do Tratamento , Adulto , Bactérias Gram-Negativas/efeitos dos fármacos , Unidades de Terapia Intensiva , Pseudomonas aeruginosa/efeitos dos fármacos , Idoso de 80 Anos ou mais , Klebsiella pneumoniae/efeitos dos fármacosRESUMO
Biofilms, particularly those formed by multiple bacterial species, pose significant economic and environmental challenges, especially in the context of medical implants. Addressing the urgent need for effective treatment strategies that do not exacerbate drug resistance, we developed a novel nanoformulation, Ce6&PMb@BPN, based on black phosphorus nanosheets (BPN) for targeted treatment of mixed-species biofilms formed by Acinetobacter baumannii (A. baumannii) and methicillin-resistant Staphylococcus aureus (MRSA).The formulation leverages polymyxin B (PMb) for bacterial targeting and chlorin e6 (Ce6) for photodynamic action. Upon near-infrared (NIR) irradiation, Ce6&PMb@BPN efficiently eliminates biofilms by combining chemotherapy, photodynamic therapy (PDT) and photothermal therapy (PTT), reducing biofilm biomass significantly within 30 min. In vivo studies on mice infected with mixed-species biofilm-coated catheters demonstrated the formulation's potent antibacterial and biofilm ablation effects. Moreover, comprehensive biosafety evaluations confirmed the excellent biocompatibility of Ce6&PMb@BPN. Taken together, this intelligently designed nanoformulation holds potential for effectively treating biofilm-associated infections, addressing the urgent need for strategies to combat antibiotic-resistant biofilms, particularly mixed-species biofilm, in medical settings.
Assuntos
Acinetobacter baumannii , Antibacterianos , Biofilmes , Staphylococcus aureus Resistente à Meticilina , Nanoestruturas , Fósforo , Fotoquimioterapia , Polimixina B , Porfirinas , Animais , Biofilmes/efeitos dos fármacos , Polimixina B/administração & dosagem , Polimixina B/farmacologia , Fósforo/química , Staphylococcus aureus Resistente à Meticilina/efeitos dos fármacos , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Antibacterianos/química , Fotoquimioterapia/métodos , Acinetobacter baumannii/efeitos dos fármacos , Nanoestruturas/química , Porfirinas/administração & dosagem , Porfirinas/química , Porfirinas/farmacologia , Clorofilídeos , Fármacos Fotossensibilizantes/administração & dosagem , Fármacos Fotossensibilizantes/farmacologia , Fármacos Fotossensibilizantes/química , Camundongos , Feminino , Terapia Fototérmica/métodos , Camundongos Endogâmicos BALB C , Farmacorresistência Bacteriana , Infecções Estafilocócicas/tratamento farmacológicoRESUMO
Sub-therapeutic doses, shorter duration of therapy, female gender, bacteremia, and renal impairment were among independent predictors of polymyxin B treatment failure. In this study, we found an association between inappropriate doses of polymyxin B (<15000 or >25000 unit/kg/day) and renal impairment. Inappropriate doses of polymyxin B were significantly associated with CrCl 20-50 mL/min (p = 0.021, ORadj 6.660, 95% CI 1.326, 33.453) and CrCl <20 mL/min (p = 0.001, ORadj 22.200, 95% CI 3.481, 141.592). By conducting sub-group analysis only using subjects with appropriate dosage, renal impairment was not associated with polymyxin B treatment failure, thus indicating that treatment failure was due to an inappropriate dose of polymyxin B, rather than renal impairment. In conclusion, renal impairment was not directly associated with treatment failure but was due to an inappropriate dosage of polymyxin B after renal adjustment
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Polimixina B/administração & dosagem , Falha de Tratamento , Dosagem/efeitos adversos , Terapêutica , Adaptação Psicológica , Bacteriemia , Insuficiência Renal/tratamento farmacológicoRESUMO
INTRODUÇÃO: O processo de hiperpigmentação cutânea envolve mecanismos bioquímicos e imunológicos que estimulam a melanogênese e apesar da nefrotoxicidade consistir na reação adversa mais relevante da polimixina B, o antimicrobiano também está associado a esta alteração. RELATO DE CASO: Caso 1: paciente masculino diagnosticado com Linfoma de Hodgkin, que desenvolveu hiperpigmentação cutânea após iniciar tratamento com meropenem, anidulafungina e polimixina B devido a um quadro de choque séptico. Caso 2: paciente masculino admitido na UTI por rebaixamento do nível de consciência e suspeita de IAMCSST, diagnosticado com endocardite e pericardite, que também apresentou hiperpigmentação cutânea durante terapia com anfotericina B e polimixina B. CONCLUSÃO: Após criteriosa avaliação da ordem cronológica e medicamentos utilizados pelos pacientes, concluímos que a polimixina B desencadeou a hiperpigmentação em ambos. Por fim, baseado ao mecanismo desta reação e aos achados científicos, estudos clínicos que possam evidenciar um provável efeito farmacológico com o uso de antagonistas H2 são necessários.
INTRODUCTION: The skin hyperpigmentation process involves biochemical and immunological mechanisms that stimulate melanogenesis and although nephrotoxicity consists of the most relevant adverse reaction of polymyxin B, it is also associated with this changes. CASE REPORT: Case 1: male patient, diagnosed with Hodgkin's Lymphoma, who developed skin hyperpigmentation after starting treatment with meropenem, anidulafungin and polymyxin B due to a septic shock. Case 2: male patient, admitted to the ICU for decreased level of consciousness and suspected STEMI, diagnosed with endocarditis and pericarditis, who also presented skin hyperpigmentation during therapy with amphotericin B and polymyxin B. CONCLUSION: After careful evaluation of chronological order and drugs used by patients, we conclude that polymyxin B caused hyperpigmentation in both patients. Finally, based on the mechanism of this reaction and the scientific findings, clinical studies that may evidence a probable pharmacological effect with the use of H2 antagonists are required.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Polimixina B/administração & dosagem , Polimixina B/efeitos adversos , Polimixina B/uso terapêutico , Hiperpigmentação/patologia , Hiperpigmentação/tratamento farmacológico , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/tratamento farmacológico , Efeitos Colaterais e Reações Adversas Relacionados a MedicamentosRESUMO
ABSTRACT Polymyxin B is one of the last resort option for carbapenem-resistant Klebsiella pneumoniae (CRKP) bloodstream infection in China. Therefore, the timing of administration of polymyxin is frequently delayed. We collected 40 cases of CRKP bloodstream infections (BSIs) treated with combinations based on polymyxin B over 30 months. The primary outcome, 30-day mortality rate, was 52.5% (21/40). Early administration of polymyxin B is meant to administer the drug within 48 h of diagnosing bacteremia. Delayed administration was considered when polymyxin B was administered after 48 h of bacteremia onset. Polymyxin B duration and total dosages were similar in the two groups (11.57 days versus 11.76 days, p = 0.919; 1306.52 mg versus 1247.06 mg, p = 0.711). Compared with delayed administration, early use of polymyxin B-based combination therapy had a significant increase in the rate of bacterial clearance (65.22% versus 29.41%, p = 0.025; OR = 0.533) and decreased 30-day mortality (39.13% versus 70.59%, p = 0.045; OR = 0.461) and overall mortality (43.48% versus 82.35%, p = 0.022; OR = 0.321).
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Polimixina B/administração & dosagem , Infecções por Klebsiella/tratamento farmacológico , Bacteriemia/tratamento farmacológico , Enterobacteriáceas Resistentes a Carbapenêmicos/efeitos dos fármacos , Antibacterianos/administração & dosagem , Infecções por Klebsiella/mortalidade , Testes de Sensibilidade Microbiana , Reprodutibilidade dos Testes , Estudos Retrospectivos , Resultado do Tratamento , Bacteriemia/mortalidade , Estimativa de Kaplan-MeierRESUMO
Abstract This clinical study investigated the effects of endodontic treatment by using different irrigants (limewater + NaOCl and polymyxin B + NaOCl) and intracanal medication on endotoxins in teeth with primary endodontic infection and radiographically visible apical periodontitis. Thirty-three teeth with necrotic pulp and periapical lesions from different patients were selected for this study. Samples were collected after the coronal opening (S1) and after instrumentation (S2). Root canals were divided in 3 groups (n = 11) according to the irrigant combination used: NaOCl + LW: 2.5% NaOCl + calcium hydroxide solution (0.14%, limewater); NaOCl + PmB: 2.5% NaOCl + 10.000 UI/mL polymyxin B; 2.5% NaOCl (control). The third sampling (S3) was performed after ethylenediaminetetraacetic acid and the fourth (S4) after samples got 14 days with intracanal medication with 2% chlorhexidine gel + calcium hydroxide. Endotoxins (lipopolysaccharide) were quantified by chromogenic Limulus amebocyte lysate (LAL). Endotoxins were detected in all root canals after the coronal opening (S1). NaOCl + PmB group presented the greatest endotoxin reduction after instrumentation (76.17%), similar to NaOCl + LW group (67.64%, p<0.05) and different from NaOCl group (42.17%, p<0.05). After intracanal medication period (S4), there was significant increase of endotoxins neutralization. It was concluded that NaOCl + PmB promoted the greatest reduction of endotoxin levels, followed by NaOCl + LW. Intracanal medications had no significant complementary role in the reduction of endotoxins at the end of the treatment
Resumo Este estudo clínico investigou os efeitos do tratamento endodôntico com uso de diferentes irrigantes (NaOCl + água de cal e NaOCl + polimixina B) e medicação intracanal sobre endotoxinas em dentes com infecção endodôntica primária e presença de lesão periapical visível radiograficamente. Foram selecionados para o estudo trinta e três dentes de pacientes que apresentavam necrose pulpar e presença de lesão periapical. As amostras foram coletadas após a abertura coronária (S1) e após a instrumentação (S2). Os canais radiculares foram divididos em 3 grupos (n = 11) de acordo com a combinação de irrigantes utilizada: NaOCl + LW:- hipoclorito de sódio 2,5% + solução de hidróxido de cálcio (água de cal 0,14%); NaOCl + PmB: hipoclorito de sódio a 2,5% + polimixina B 10.000 UI/mL; NaOCl (controle): hipoclorito de sódio a 2,5%. A terceira coleta (S3) foi realizada após aplicação do ácido etilenodiamino tetra acético (EDTA) e a quarta coleta (S4) após 14 dias de medicação intracanal de hidróxido de cálcio + clorexidina gel 2%. Endotoxinas (lipopolissacarídeos) foram quantificadas pelo ensaio cromogênico do lisado de amebócitos de Limulus (LAL). Endotoxinas foram detectadas em todos os canais radiculares após abertura coronária (S1). Grupo NaOCl + PmB apresentou a maior redução de endotoxinas após a instrumentação (76,17%), sendo similar ao grupo NaOCl + LW (67,64%, P >.05) e diferente do grupo NaOCl (42,17%, P <.05). Após o período de medicação intracanal, houve aumento significativo da neutralização de endotoxinas. Concluiu-se que NaOCl + PmB promoveu a maior redução dos níveis de endotoxinas, seguido de NaOCl + LW. A medicação intracanal não teve um papel complementar significativo na redução de endotoxinas no final do tratamento.
Assuntos
Humanos , Masculino , Feminino , Adulto , Endotoxinas/administração & dosagem , Polimixina B/administração & dosagem , Tratamento do Canal Radicular/métodosRESUMO
OBJETIVO: Caracterizar a toxicidade da polimixina B (PmxB) em células renais em dosagem e tempos diferentes. MÉTODOS: Células LLC-PK1, cultivadas em placas multiwell de 12 poços, foram divididas nos seguintes grupos: Controle (CTL) - células mantidas em meio DMEM suplementado a 5%; G1 - células expostas à concentração de 75mM de PmxB; G2 - células expostas à concentração de 375mM de PmxB. Cada grupo foi avaliado nos tempos de 24, 48 e 72 horas quanto à viabilidade celular (Acridine Orange/Brometo de Etídio) e apoptose (Hoechst 33342). RESULTADOS: Os dados demonstraram a viabilidade celular e a apoptose à exposição de três doses de PmxB em três intervalos de tempo, com um aumento significativo da toxicidade à elevação das doses e ao maior tempo de permanência no antibiótico para apoptose. CONCLUSÃO: A citotoxicidade pela PmxB, no modelo de cultivo celular, se mostrou tempo e dose dependente, aumentando com a maior exposição e maior dose de antibiótico.
OBJECTIVE: To characterize the toxicity of polymyxin B (PmxB) in renal cell in different dosage and times. METHODS: LLC-PK1 cells grown in 12 well multiwell plates were divided into the following groups: Control (CTL) - cells maintained in DMEM supplemented with 5%; G1 - cells exposed to concentration of 75µM PmxB G2 - cells exposed to concentration of 375µM PmxB. Each group was assessed at 24,48 and 72 hours as for cell viability (Acridine orange/ethidium bromide) and apoptosis (Hoechst 33342). RESULTS: The data demonstrate the cell viability and apoptosis exposure of three doses of PmxB in three time intervals, with a significant increase in toxicity to high doses and longer duration of stay in the antibiotic to apoptosis. CONCLUSION: Cytotoxicity by PmxB in cell culture model, showed to be time and dose dependent, increasing with increased exposure and higher dose of antibiotic.
Assuntos
Antibacterianos/administração & dosagem , Antibacterianos/toxicidade , Apoptose , Células LLC-PK1 , Técnicas In Vitro , Polimixina B/administração & dosagem , Polimixina B/toxicidade , Sobrevivência Celular , Estudos de Avaliação como AssuntoRESUMO
resumo: foram analisadas 50 amostras de dez diferentes marcas comerciais de queijo tipo "Minas Frescal", comercializados em supermecados do Rio de Janeiro.Foram pesquisados os microrganismos indicadores de contaminaçäo fecal pelo método do número mais provável.Os coliformes totais variaram de 2, 7*10elevado a terceira/g a 2, 4*10elevado a sexta/g e os coliformes fecais de 2*10/g a 2, 1*10elevado a sexta/g.Das amostras examinadas, 80 por cento mostraram precárias condiçöes higiênico-sanitárias, de acordo com os limites estabelecidos pelos padröes do Ministério da Saúde(DNVS).paralelamente, foram pesquisaas Yersinia spp por três diferentes metodologias.o método do pré-enriquecimento a 26ºC/48 horas e posterior tratamento alcalino sequido de semeadura em agar desoxicolato citrato permitiu a identificaçäo de 11 amostras de Y.frederiksenii-0:16a, 16b-Xo.Pelo método do plaqueamento direto, apenas uma amostra de Y.intermedia-NAG-Xo no meio agar por 7 a 21 dias näo permitiu o isolamento de nenhuma amostra.Essas amostras de yersinia spp foram submetidas aos testes de produçäo de enterotoxina termoestável, autoaglutinaçäo, cálcio-dependência, capacidade de ligaçäo ao cristal violeta, atividade de piraminamidase, atividade enzimática extracelular, com objetivo de avaliar o seu comportamento biológico.Todas se comportam negativamente, com exceçäo de uma amostra de Y.frederiksenii que foi protease positiva.Finalmente, o perfil de sensibilidade das Yersinia spp isoladas, mosxtrou uma multiresistência em relaçäo à vários antimicrobianos.Apresentaram uma melhor sensibilidad ao ácido nalidíxico, amicacina, cloranfenicol, gentamicina, norfloxacina, polimixina B e Tobramicina.Todas as amostras de Yersinia spp isoladas no presente estudo tiveram a capacidade de produzir B-lactamase, através do método de Nitrocefin.
Assuntos
Yersinia , Carbenicilina/administração & dosagem , Cefalotina/uso terapêutico , Queijo , Enterobacteriaceae/efeitos dos fármacos , Ampicilina/uso terapêutico , Ácido Nalidíxico/administração & dosagem , Antibacterianos/uso terapêutico , Contaminação de Alimentos/análise , Polimixina B/administração & dosagem , Polimixina B/uso terapêutico , Tobramicina/administração & dosagem , Amicacina/administração & dosagem , Amicacina/uso terapêutico , Gentamicinas/uso terapêutico , Cloranfenicol/administração & dosagem , Cloranfenicol/uso terapêuticoRESUMO
Um dos grandes desafios no desenvolvimento de fórmulas farmacêuticas e cosméticas é a adequaçäo de seus sistemas conservantes. No presente trabalho, empregou-se método de otimizaçäo destes para suspensäo oftálmica de dexametasona e sulfato de polimixina B. O experimento foi conduzido utilizando-se planejamento estatístico do tipo simplex-lattice. A matriz de ensaio contemplou 17 fórmulas sendo que as variáveis independentes foram as concentraçöes de conservantes álcool feniletílico (X+) e digluconato de clorhexidina (X2) e EDTA (X3). A variável dependente ou resposta foi o valor D obtido do desafio das fórmulas com Pseudomonas aeruginosa, Pseudomonas cepacia, Staphylococcus aureus, Candida albicans e Aspergillus niger, ...